NZ707930A - Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases - Google Patents

Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases

Info

Publication number
NZ707930A
NZ707930A NZ707930A NZ70793011A NZ707930A NZ 707930 A NZ707930 A NZ 707930A NZ 707930 A NZ707930 A NZ 707930A NZ 70793011 A NZ70793011 A NZ 70793011A NZ 707930 A NZ707930 A NZ 707930A
Authority
NZ
New Zealand
Prior art keywords
prostate cancer
vegf
castration
met
treatment
Prior art date
Application number
NZ707930A
Inventor
David Smith
Maha Hussain
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of NZ707930A publication Critical patent/NZ707930A/en

Links

Abstract

The disclosure relates to methods for treating bone cancer, prostate cancer or bone cancer associated with prostate cancer, comprising administering a compound that dually modulates MET and VEGF. In particular, the methods are for treating castration-resistant prostate cancer (CRPC) and osteoblastic bone metastases and centres. The compound (compound I - cabozantinib) contains a quinolone, dicarboxamide and a cyclopropane functional groups.
NZ707930A 2010-09-27 2011-09-26 Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases NZ707930A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38695910P 2010-09-27 2010-09-27
US201161481671P 2011-05-02 2011-05-02
NZ60921211 2011-09-26

Publications (1)

Publication Number Publication Date
NZ707930A true NZ707930A (en) 2016-09-30

Family

ID=56989724

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ707930A NZ707930A (en) 2010-09-27 2011-09-26 Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases

Country Status (1)

Country Link
NZ (1) NZ707930A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694259C2 (en) * 2017-10-16 2019-07-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method of castration-resistant prostate cancer treatment
RU2700573C2 (en) * 2017-10-16 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method of castration-resistant prostate cancer treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694259C2 (en) * 2017-10-16 2019-07-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method of castration-resistant prostate cancer treatment
RU2700573C2 (en) * 2017-10-16 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method of castration-resistant prostate cancer treatment

Similar Documents

Publication Publication Date Title
MX352926B (en) Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases.
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
MX2015007205A (en) Histone demethylase inhibitors.
CR20120202A (en) METHODS AND COMPOSITIONS TO TREAT CANCER
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
AU2011328009A8 (en) Compounds and methods for treating pain
EA201490944A1 (en) DOUBLE MET AND VEGF INHIBITOR FOR CANCER TREATMENT
IN2014DN08812A (en)
WO2013056148A3 (en) Scd1 antagonists for treating cancer
MX343135B (en) Fumagillol type compounds and methods of making and using same.
MX2015014046A (en) Drug combinations to treat cancer.
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
PH12015502342B1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EA201890598A3 (en) ANTIANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION RESISTANT CANCER OF THE PROSTATE
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
WO2011130697A3 (en) Tissue targeting
NZ707930A (en) Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
MX350868B (en) MEDICAMENTS and METHODS FOR TREATING CANCER.
EP2575766A4 (en) Novel pharmaceutical compounds
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 SEP 2018 BY AJ PARK

Effective date: 20170426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2019 BY CPA GLOBAL

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2020 BY CPA GLOBAL

Effective date: 20190815

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2021 BY CPA GLOBAL

Effective date: 20200813

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2022 BY CPA GLOBAL

Effective date: 20210812

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2023 BY CPA GLOBAL

Effective date: 20220811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2024 BY CPA GLOBAL

Effective date: 20230811